Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...

Following Merus’ splash last month with a “best-in-disease profile” for its head and neck cancer bispecific, Bicara touted ...